Tepkinly / Epkinly (Epcoritamab) is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and in relapsed or refractory follicular lymphoma (FL).
Dosage:
DLBCL and High-grade B-cell Lymphoma
| Cyclea | Day of treatment | Dose of Tepkinly / Epkinly | |
|
Cycle 1
|
1 | Step-up dose 1 | 0.16 mg |
| 8 | Step-up dose 2 | 0.8 mg | |
| 15 | First full dose | 48 mg | |
| 22 | 48 mg | ||
| Cycles 2 and 3 | 1, 8, 15 and 22 | 48 mg | |
| Cycles 4 to 9 | 1 and 15 | 48 mg | |
| Cycle 10 and beyond | 1 and 15 | 48 mg | |
aCycle = 28 days
Tepkinly / Epkinly as Monotherapy for FL
| Cyclea | Day | Dose of Tepkinly / Epkinly | |
|
Cycle 1
|
1 | Step-up dose 1 | 0.16 mg |
| 8 | Step-up dose 2 | 0.8 mg | |
| 15 | Step-up dose 3 | 3 mg | |
| 22 | First full dose | 48 mg | |
| Cycles 2 and 3 | 1, 8, 15 and 22 | 48 mg | |
| Cycles 4 to 9 | 1 and 15 | 48 mg | |
| Cycle 10 and beyond | 1 and 15 | 48 mg | |
aCycle = 28 days
Tepkinly / Epkinly in combination with Lenalidomide and Rituximab for FL
| Cyclea | Day | Dose of Tepkinly / Epkinly | |
|
Cycle 1
|
1 | Step-up dose 1 | 0.16 mg |
| 8 | Step-up dose 2 | 0.8 mg | |
| 15 | Step-up dose 3 | 3 mg | |
| 22 | First full dose | 48 mg | |
| Cycles 2 and 3 | 1, 8, 15 and 22 | 48 mg | |
| Cycles 4 to 12 | 1 | 48 mg | |
aCycle = 28 days
Adverse effects:
- Cytokine Release Syndrome (CRS)
- Injection site reactions,
- Fatigue, musculoskeletal pain,
- Fever,
- Diarrhea
- COVID-19
- Rash
- Abdominal pain.
Strength:Injection:4 mg/0.8 mL, 48 mg/0.8 mL in a single-dose vial
Storage:Store in the refrigerator at 2° to 8°C (36°F to 46°F).
Revisiones
There are no reviews yet.